Literature DB >> 8603963

Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients.

K A Gebo1, R D Moore, J C Keruly, R E Chaisson.   

Abstract

To identify risk factors for pneumococcal infection among human immunodeficiency virus-infected patients, a nested case-control study was done in an urban university human immunodeficiency virus clinic. Subjects with pneumococcal illness seen between 1 January 1990 and 1 July 1994 (n=85) were randomly matched to controls from the same population. Patients with pneumococcal disease were more likely than controls to be African Americans (adjusted odds ratio [OR]=3.92), have <200 CD4 cells/mm3 (adjusted OR=3.38), have a history of any pneumonia (adjusted OR=3.28), and have an albumin level of <3.0 g/dL (adjusted OR=6.25). Use of zidovudine (adjusted OR=0.38) and pneumococcal vaccination when the subject had >200 CD4 cells/mm3 (adjusted OR=0.22) were less common in cases than in controls. Similar results were found when only cases with infections of usually sterile sites were analyzed. Pneumococcal vaccine may be most protective when it is administered before advanced immunodeficiency develops.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8603963     DOI: 10.1093/infdis/173.4.857

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

Review 1.  1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA).

Authors: 
Journal:  Infect Dis Obstet Gynecol       Date:  2000

2.  2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.

Authors: 
Journal:  Infect Dis Obstet Gynecol       Date:  2002

Review 3.  Prophylaxis against opportunistic infections in patients infected with the human immunodeficiency virus.

Authors:  L W Cheever; R E Chaisson; J E Gallant
Journal:  West J Med       Date:  1996 Jul-Aug

4.  Race-related differences in functional antibody response to pneumococcal vaccination in HIV-infected individuals.

Authors:  Myroslawa Happe; Devadoss J Samuvel; Jennifer A Ohtola; Jeff E Korte; M A Julie Westerink
Journal:  Vaccine       Date:  2019-02-21       Impact factor: 3.641

5.  The association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection.

Authors:  Nancy F Crum-Cianflone; Mollie Roediger; Kathy Huppler Hullsiek; Anuradha Ganesan; Michael Landrum; Amy Weintrob; Brian Agan; Sheila Medina; Jeremy Rahkola; Braden Hale; Edward N Janoff
Journal:  Vaccine       Date:  2010-09-29       Impact factor: 3.641

Review 6.  Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.

Authors:  Kuan-Yeh Lee; Mao-Song Tsai; Kuang-Che Kuo; Jen-Chih Tsai; Hsin-Yun Sun; Aristine C Cheng; Sui-Yuan Chang; Chen-Hsiang Lee; Chien-Ching Hung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  Bloodstream infections in HIV-infected patients.

Authors:  Lucia Taramasso; Paola Tatarelli; Antonio Di Biagio
Journal:  Virulence       Date:  2016-04-02       Impact factor: 5.882

8.  Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study.

Authors:  Maria C Rodriguez-Barradas; Joseph Goulet; Sheldon Brown; Matthew Bidwell Goetz; David Rimland; Michael S Simberkoff; Kristina Crothers; Amy C Justice
Journal:  Clin Infect Dis       Date:  2008-04-01       Impact factor: 9.079

9.  Vaccination in HIV-infected Patients.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.663

10.  Vaccination in patients with HIV infection.

Authors:  Todd D Gleeson; Mark R Wallace; Sybil A Tasker
Journal:  Curr Infect Dis Rep       Date:  2006-03       Impact factor: 3.663

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.